Welcome to our dedicated page for Adamas Pharma news (Ticker: ADMS), a resource for investors and traders seeking the latest updates and insights on Adamas Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adamas Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adamas Pharma's position in the market.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced the granting of restricted stock units for 106,500 shares to eight new employees. These units will vest over three years and were issued under the 2016 Inducement Plan, approved by the board in March 2016, as per Nasdaq regulations. This move aims to attract talented individuals to bolster the company's workforce, which is focused on developing innovative therapies for neurological diseases.
Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) has been named a finalist in the UCSF Health Awards 2021 in the New Therapeutics category for its innovative drug GOCOVRI® (amantadine). This FDA-approved medication uniquely addresses both OFF episodes and dyskinesia in Parkinson’s disease patients. GOCOVRI is taken once daily at bedtime, optimizing its effectiveness during waking hours. CEO Neil F. McFarlane emphasized the honor of this recognition, reflecting the impact of their therapeutic on patient quality of life.
Adamas Pharmaceuticals (ADMS) announced the presentation of five posters at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, occurring from September 17-22, 2021. The posters will focus on GOCOVRI® (amantadine), the first FDA-approved treatment for dyskinesia in Parkinson’s patients on levodopa therapy. Key analyses highlight GOCOVRI's efficacy in managing motor complications, showing significant reductions in OFF and dyskinesia. GOCOVRI consistently demonstrates a unique treatment impact, supporting its role as a cost-effective adjunctive therapy for Parkinson’s disease.
Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) announced the granting of restricted stock units for 94,750 shares to seven new employees. These units will vest over three years and are part of the 2016 Inducement Plan approved by the board in March 2016. This initiative aims to attract new talent to enhance the company's focus on developing innovative therapies for neurological diseases, ultimately addressing the challenges faced by patients and caregivers.
Adamas Pharmaceuticals (NASDAQ: ADMS) will present at two virtual investor conferences in September 2021. The first, the H.C. Wainwright 23rd Annual Global Investment Conference, features a pre-recorded presentation available from September 13 at 7:00 am ET. The second, the Cantor Fitzgerald Global Healthcare Conference, is scheduled for September 29 at 4:40 pm ET. Replays will be accessible on the company's investor relations webpage for about 30 days. Adamas focuses on innovative treatments for neurological diseases.
Adamas Pharmaceuticals (Nasdaq: ADMS) has granted restricted stock units (RSUs) to three new employees, totaling 38,500 shares. These RSUs will vest over three years and are part of the Adamas Pharmaceuticals 2016 Inducement Plan, approved by the board in March 2016. The plan is designed to attract new talent to advance the company's mission of delivering innovative neurological therapies. For further details, visit www.adamaspharma.com.
Adamas Pharmaceuticals (Nasdaq: ADMS) reported a 17% increase in total revenues to $22.0 million for Q2 2021, driven by GOCOVRI sales of $20.1 million, a 12% rise from the previous year. New paid prescriptions for GOCOVRI surged 97% to approximately 730. R&D expenses fell to $1.4 million, down from $2.6 million year-over-year, while SG&A expenses rose to $29.2 million. The net loss increased to $12.3 million, or $0.27 per share. As of June 30, 2021, cash reserves stood at $118.3 million, bolstered by a $66.5 million stock sale earlier this year.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) will report its second quarter 2021 financial results on August 9, after market close. Following the announcement, management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and offer a corporate update. Investors can access the call by dialing provided numbers or through the company's website, where a replay will be available for about 30 days. Adamas focuses on innovative therapies for neurological diseases, aiming to alleviate the patient and caregiver burden.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announces the issuance of two patents for GOCOVRI® (amantadine) extended-release capsules: U.S. Patent No. 11,065,213 and U.S. Patent No. 11,077,073. These patents enhance the company's IP portfolio, which now totals 17 U.S. patents for GOCOVRI, valid until 2038. GOCOVRI is the first FDA-approved treatment for dyskinesia in Parkinson's patients on levodopa therapy. Additionally, a new patent for ADS-4101, an investigational drug for epilepsy, has been issued in Japan.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) has granted restricted stock units to four new employees, allowing them to acquire 44,500 shares of common stock. These units will vest over three years and are part of the 2016 Inducement Plan, established to attract new talent to the company. This initiative underscores Adamas' commitment to building a robust workforce aimed at developing innovative treatments for neurological diseases, reflecting its strategic focus on enhancing its portfolio and addressing patient needs.
